Prime Highlights-
- Health Innovation KSS has appointed Dr Nicolas Huber and Gautam Kainth as non-executive directors to help speed up the spread of innovation across health and care.
- The appointments come as the organisation prepares to launch its strategy to 2030, with a focus on partnerships and growth in data, digital and AI.
Key Facts-
- Huber leads one of the UK’s leading medical device translation programmes at King’s College London.
- Kainth has overseen the deployment of more than US$1bn in capital globally.
Background-
Health Innovation Kent Surrey Sussex (KSS) has appointed Dr Nicolas Huber and Gautam Kainth as non-executive directors. The new directors will help the organisation speed up the adoption and spread of innovation across health and care.
Chair Jane Ollis said she is delighted to welcome both. They join at a pivotal moment, she said, as the organisation prepares to launch its strategy to 2030. Their insight and challenge will help strengthen partnerships across health and life sciences, build its leadership in data, digital and AI, and boost the impact for patients, communities and the wider health and care system.
Huber is director of commercial operations and partnerships at the London Institute for Healthcare Engineering at King’s College London. There, he leads one of the UK’s leading medical device translation programmes. He previously served as director of innovation at King’s College London, led a University of Cambridge spin-out as chief executive and mentored health technology start-ups.
Kainth is managing partner at TCP Health Ventures, a medtech-focused healthcare fund. He has more than two decades of experience in healthcare innovation, investment and growth, and has overseen more than US$1bn in capital worldwide.
He knows how to help new health technologies move from development to scale. His background in life sciences, medical technology and investment will support the organisation as it deepens ties with innovators and expands its data, digital and AI-enabled work.
